A human liver chimeric mouse model for non-alcoholic fatty liver disease

The accumulation of neutral lipids within hepatocytes underlies non-alcoholic fatty liver disease (NAFLD), which affects a quarter of the world’s population and is associated with hepatitis, cirrhosis, and hepatocellular carcinoma. Despite insights gained from both human and animal studies, our unde...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JHEP reports 2021-06, Vol.3 (3), p.100281-100281, Article 100281
Hauptverfasser: Bissig-Choisat, Beatrice, Alves-Bezerra, Michele, Zorman, Barry, Ochsner, Scott A., Barzi, Mercedes, Legras, Xavier, Yang, Diane, Borowiak, Malgorzata, Dean, Adam M., York, Robert B., Galvan, N. Thao N., Goss, John, Lagor, William R., Moore, David D., Cohen, David E., McKenna, Neil J., Sumazin, Pavel, Bissig, Karl-Dimiter
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The accumulation of neutral lipids within hepatocytes underlies non-alcoholic fatty liver disease (NAFLD), which affects a quarter of the world’s population and is associated with hepatitis, cirrhosis, and hepatocellular carcinoma. Despite insights gained from both human and animal studies, our understanding of NAFLD pathogenesis remains limited. To better study the molecular changes driving the condition we aimed to generate a humanised NAFLD mouse model. We generated TIRF (transgene-free Il2rg-/-/Rag2-/-/Fah-/-) mice, populated their livers with human hepatocytes, and fed them a Western-type diet for 12 weeks. Within the same chimeric liver, human hepatocytes developed pronounced steatosis whereas murine hepatocytes remained normal. Unbiased metabolomics and lipidomics revealed signatures of clinical NAFLD. Transcriptomic analyses showed that molecular responses diverged sharply between murine and human hepatocytes, demonstrating stark species differences in liver function. Regulatory network analysis indicated close agreement between our model and clinical NAFLD with respect to transcriptional control of cholesterol biosynthesis. These NAFLD xenograft mice reveal an unexpected degree of evolutionary divergence in food metabolism and offer a physiologically relevant, experimentally tractable model for studying the pathogenic changes invoked by steatosis. Fatty liver disease is an emerging health problem, and as there are no good experimental animal models, our understanding of the condition is poor. We here describe a novel humanised mouse system and compare it with clinical data. The results reveal that the human cells in the mouse liver develop fatty liver disease upon a Western-style fatty diet, whereas the mouse cells appear normal. The molecular signature (expression profiles) of the human cells are distinct from the mouse cells and metabolic analysis of the humanised livers mimic the ones observed in humans with fatty liver. This novel humanised mouse system can be used to study human fatty liver disease. [Display omitted] •Human liver chimeric mice fed a western diet develop NAFLD.•Within the same chimeric liver, human hepatocytes developed pronounced steatosis while murine hepatocytes remained normal.•Unbiased metabolomics and lipidomics of fatty humanised mouse livers revealed signatures of clinical NAFLD.•Transcriptomic analyses showed that molecular responses diverged sharply between murine and human hepatocytes.•This humanised NAFLD model is
ISSN:2589-5559
2589-5559
DOI:10.1016/j.jhepr.2021.100281